Celmatix Appoints Seasoned Litigator Craig Bolton as General Counsel to Support Pipeline Expansion Strategy

NEW YORK–()–Celmatix Inc., the leading women’s health biotech focused uniquely on ovarian biology, today announced that Craig Bolton has been appointed as General Counsel. Bolton joins the Celmatix executive team after representing the biotech as outside counsel since 2019 and will play a critical role in supporting the company in ongoing therapeutic pipeline expansion and progress of their lead AMHR2 agonist program.

“As we build on the continued success of our lead AMHR2 agonist program with additional innovative opportunities in women’s health therapeutics, we are fortunate to have recruited an attorney with such breadth of experience,” Dr. Piraye Yurttas Beim, Celmatix Founder and CEO commented. “Craig has been an excellent partner to Celmatix as outside counsel, and we are thrilled to have him now join our executive team.”

This announcement follows the company’s recent appointment of women’s health pioneer Dr. Bart CJM Fauser to the Chairmanship of its Scientific Advisory Board (SAB) and newly formed Clinical Trial Steering Committee.

“Since working with Celmatix, I have been deeply impressed by the strength of the team, their dedication to upholding high standards in scientific integrity, and their unwavering commitment to this underserved therapeutic area,” said Mr. Bolton. “It is a great honor to now join as General Counsel and help Celmatix pursue its vital mission to improve the health and lives of women around the world.”

Mr. Bolton is a seasoned litigator and counselor who has spent over a decade guiding both emerging and established biotech companies through complex commercial, intellectual property, and other business disputes. He has routinely advised boards of directors and special committees regarding litigation and corporate governance matters. Prior to joining Celmatix, Mr. Bolton was a partner at two nationally recognized law firms and an attorney at Wilson Sonsini Goodrich & Rosati. Mr. Bolton graduated from New York University School of Law and was a law clerk to the Honorable William J. Martini of the United States District Court for the District of New Jersey.

About Celmatix

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 agonist program focused on ovarian senescence, and collaborations with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information, visit the company’s website at www.celmatix.com


Recent Articles

Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.